The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations. A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.
The clinical steroidal selective class="Chemical">pan> class="Gene">estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood-brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations. A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.
Authors: Suzanne E Wardell; Erik R Nelson; Christina A Chao; Holly M Alley; Donald P McDonnell Journal: Endocr Relat Cancer Date: 2015-07-10 Impact factor: 5.678
Authors: R Clarke; T C Skaar; K B Bouker; N Davis; Y R Lee; J N Welch; F Leonessa Journal: J Steroid Biochem Mol Biol Date: 2001 Jan-Mar Impact factor: 4.292
Authors: S W Fanning; L Hodges-Gallagher; D C Myles; R Sun; C E Fowler; I N Plant; B D Green; C L Harmon; G L Greene; P J Kushner Journal: Nat Commun Date: 2018-06-18 Impact factor: 14.919
Authors: Jun Liang; Robert Blake; Jae Chang; Lori S Friedman; Simon Goodacre; Steven Hartman; Ellen Rei Ingalla; James R Kiefer; Tracy Kleinheinz; Sharada Labadie; Jun Li; Kwong Wah Lai; Jiangpeng Liao; Vidhi Mody; Neville McLean; Ciara Metcalfe; Michelle Nannini; Daniel Otwine; Yingqing Ran; Nick Ray; Fabien Roussel; Amy Sambrone; Deepak Sampath; Maia Vinogradova; John Wai; Tao Wang; Kuen Yeap; Amy Young; Jason Zbieg; Birong Zhang; Xiaoping Zheng; Yu Zhong; Xiaojing Wang Journal: ACS Med Chem Lett Date: 2020-05-26 Impact factor: 4.345
Authors: Hu Chen; Yunlong Lu; Rui Xiong; Carlo I Rosales; Cassandre Coles; Kana Hamada; Nuria Asad; Gregory R J Thatcher; Amy W Lasek Journal: Alcohol Clin Exp Res Date: 2022-05-29 Impact factor: 3.928